Serum Glial Fibrillary Acidic Protein (GFAP) as a Potential Biomarker for Monitoring Postoperative Complications in Deep Brain Stimulation Surgery DOI Creative Commons
Anika Frank,

Jonas Arjomand,

Jonas Bendig

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 18, 2024

Abstract Deep brain stimulation (DBS) is an efficient treatment for movement disorders, most commonly Parkinson’s Disease (PD), dystonia and essential tremor. DBS surgery carries risks, e.g. the risk of delayed peri-lead edema (PLE) postoperative cognitive decline. The mechanisms these complications are not fully understood there no established biomarker to screen after surgery. To assess whether serum glial fibrillary acid protein (sGFAP) might constitute a potentially useful detect surgery, we measured sGFAP neurofilament light chain (sNfl) in 58 patients undergoing at our center. Both markers increased transiently Serum GFAP returned baseline weeks, whereas sNfl only months. Patients with poorer preoperative performance had higher values, relationship patient characteristics was closer than sNfl. These properties suggest that can be valuable monitor

Language: Английский

Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers DOI Creative Commons
Dietmar Rudolf Thal, Koen Poesen, Rik Vandenberghe

et al.

Molecular Neurodegeneration, Journal Year: 2025, Volume and Issue: 20(1)

Published: March 14, 2025

Abstract Alzheimer’s disease (AD) is neuropathologically characterized by the extracellular deposition of amyloid-β peptide (Aβ) and intraneuronal accumulation abnormal phosphorylated tau (τ)-protein (p-τ). Most frequently, these hallmark lesions are accompanied other co-pathologies in brain that may contribute to cognitive impairment, such as vascular lesions, transactive-response DNA-binding protein 43 (TDP-43), and/or α-synuclein (αSyn) aggregates. To estimate extent AD patients, several biomarkers have been developed. Specific tracers target visualize Aβ plaques, p-τ αSyn pathology or inflammation positron emission tomography. In addition imaging biomarkers, cerebrospinal fluid, blood-based biomarker assays reflecting AD-specific non-specific processes either already clinical use development. this review, we will introduce pathological brain, related discuss what respective determined at post-mortem histopathological analysis. It became evident initial stages plaque not detected with currently available biomarkers. Interestingly, precedes deposition, especially beginning when unable detect it. Later, takes lead accelerates pathology, fitting well known evolution measures over time. Some still lack clinically established today, TDP-43 cortical microinfarcts. summary, specific for AD-related pathologies allow accurate diagnosis based on pathobiological parameters. Although current excellent pathologies, they fail which analysis required. Accordingly, neuropathological studies remain essential understand development early stages. Moreover, there an urgent need co-pathologies, limbic predominant, age-related encephalopathy-related modify interacting p-τ. Novel approaches vesicle-based cryptic RNA/peptides help better future.

Language: Английский

Citations

2
Blood biomarkers for clinical applications in Alzheimer's disease: A narrative review DOI Creative Commons
Huijun Li, Zhe Wang

NeuroMarkers., Journal Year: 2025, Volume and Issue: 2(2), P. 100078 - 100078

Published: March 27, 2025

Language: Английский

Citations

2
Plasma IL-6 levels and their association with brain health and dementia risk: A population-based cohort study DOI Creative Commons
Zhengyang Zhao, Jiashuo Zhang, Yulu Wu

et al.

Brain Behavior and Immunity, Journal Year: 2024, Volume and Issue: 120, P. 430 - 438

Published: June 17, 2024

Recent studies have associated immune abnormalities with dementia. IL-6 is a crucial cytokine in inflammatory responses, and recent evidence has linked elevated levels to changes brain structure cognitive decline. However, the connection between levels, cognition, volumes, dementia risk requires exploration large prospective cohorts.

Language: Английский

Citations

9
UK Biobank—A Unique Resource for Discovery and Translation Research on Genetics and Neurologic Disease DOI
Hannah Taylor,

Melissa Lewins,

M. George B. Foody

et al.

Neurology Genetics, Journal Year: 2025, Volume and Issue: 11(1)

Published: Jan. 17, 2025

UK Biobank is a large-scale prospective study with extensive genetic and phenotypic data from half million adults. Participants, aged 40 to 69, were recruited the general population between 2006 2010. During recruitment, participants completed questionnaires covering lifestyle medical history, underwent physical measurements, provided biological samples for long-term storage. Whole-cohort assays have been conducted, including biochemical markers, genotyping, whole-exome whole-genome sequencing, as well proteomics metabolomics in large subsets of cohort, potential additional future. Participants consented link their electronic health records, enabling identification outcomes over time. Research studies using already enhanced our understanding role variation neurologic disease, offering insights into therapeutic approaches. The integration imaging has led significant discoveries regarding relationship variants brain structure function, particularly Alzheimer disease Parkinson disease. Genetic also allowed Mendelian randomization analyses be performed, further investigation causality associations behavioral physiologic factors-such diet blood pressure-and outcomes. Furthermore, proteomic useful identifying new drug targets enhancing risk prediction algorithms that are increasingly applied clinical practice identify those at higher risk. As continues enhanced, cases accrue time, will become valuable both discovery translational research on genetics

Language: Английский

Citations

1
Astrocyte and oligodendrocyte pathology in Alzheimer's disease DOI Creative Commons

Rania Ziar,

Paul J. Tesar, Benjamin L.L. Clayton

et al.

Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown, P. e00540 - e00540

Published: Feb. 1, 2025

Astrocytes and oligodendrocytes, once considered passive support cells, are now recognized as active participants in the pathogenesis of Alzheimer's disease. Emerging evidence highlights critical role that these glial cells play pathological features Alzheimer's, including neuroinflammation, excitotoxicity, synaptic dysfunction, myelin degeneration, which contribute to neurodegeneration cognitive decline. Here, we review current understanding astrocyte oligodendrocyte pathology disease highlight research supports therapeutic potential modulating functions treat

Language: Английский

Citations

1
Neuroinflammatory fluid biomarkers in patients with Alzheimer’s disease: a systematic literature review DOI Creative Commons
Michael T. Heneka, Serge Gauthier,

Sagar Anil Chandekar

et al.

Molecular Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: March 6, 2025

Neuroinflammation is associated with both early and late stages of the pathophysiology Alzheimer's disease (AD). Fluid biomarkers are gaining significance in clinical practice for diagnosis presymptomatic stages, monitoring, prognosis. This systematic literature review (SLR) aimed to identify fluid neuroinflammation related across AD continuum examined long-term outcomes changes biomarkers. The SLR was conducted per Cochrane Handbook Systematic Reviews Interventions Preferred Reporting Items Meta-Analyses (PRISMA) guidelines. We used PubMed®, Embase®, Collaboration databases search articles English (between 2012 2022) on or mild cognitive impairment due AD, using "neuroinflammation" other "immune" strings. Two independent reviewers screened titles data from full-text SLR. After initial screening, 54 studies were prioritized extraction based upon their relevance research questions. Nine YKL-40, seven sTREM2, 11 GFAP relationship between neuroinflammatory stage disease. longitudinal further explored association Cerebrospinal (CSF) levels YKL-40 elevated patients dementia, while CSF sTREM2 more strongly preclinical symptomatic AD. Plasma remained consistently dementia individuals β-amyloid pathology. Longitudinal plasma appeared be predictive decline over time. Neuroinflammatory progression. More MCI needed validate diagnosis, prognosis practice.

Language: Английский

Citations

1
Multi-pathway blood biomarkers to target and monitor multidimensional prevention of cognitive and functional decline (nested in the IN-TeMPO study framed within the world-wide FINGERS network) DOI Creative Commons
Gessica Sala, Luca Cuffaro, Federico Emanuele Pozzi

et al.

Frontiers in Aging Neuroscience, Journal Year: 2025, Volume and Issue: 17

Published: May 7, 2025

As the population ages, identification of preventive strategies able to delay cognitive and functional decline associated with aging represents a major challenge. To date, multidimensional approaches seem be effective in reducing or delaying onset age-related diseases. The multicentric randomized controlled trial IN-TeMPO (ItaliaN study Tailored Multidomain interventions Prevent community-dwelling Older adults, ClinicalTrials.gov ID NCT06248723), framed within World-Wide FINGERS network, aims verify efficacy guided multidomain preventing decline. Within this study, we will explore comprehensive array established exploratory blood biomarkers several pathologic processes, including Alzheimer's disease (AD), neurodegeneration, inflammation, senescence sarcopenia, stratify subject risk assess effect on biomarkers. ApoE4 status plasma p-tau217 NfL (neurodegeneration), GFAP IL-6 (inflammation), GDF-15 (senescence/sarcopenia) evaluated all subjects (n = 1,662) both at baseline end (12 months). Exploratory additional measured same time points subgroup 100 subjects: BDNF, ghrelin, IGF-1, irisin redox as markers sarcopenia/senescence oxidative stress, gamma-H2AX PBMCs marker senescence, amyloid beta aggregates plasma, urine erythrocytes supportive AD. Untargeted metabolomics analysis untargeted volatilomics whole performed molecular alterations that may pathogenesis progression diseases frail older adults aim identifying novel potential clinical use multiple laboratory can contribute early trajectories mechanisms underlying multidisciplinary pathological processes.

Language: Английский

Citations

1
Blood-Based Biomarkers in Alzheimer’s Disease: Advancing Non-Invasive Diagnostics and Prognostics DOI Open Access
Mrinmay Dhauria, Ritwick Mondal, Shramana Deb

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 10911 - 10911

Published: Oct. 10, 2024

Alzheimer’s disease (AD), the most prevalent form of dementia, is expected to rise dramatically in incidence due global population aging. Traditional diagnostic approaches, such as cerebrospinal fluid analysis and positron emission tomography, are expensive invasive, limiting their routine clinical use. Recent advances blood-based biomarkers, including amyloid-beta, phosphorylated tau, neurofilament light, offer promising non-invasive alternatives for early AD detection monitoring. This review synthesizes current research on these highlighting potential track pathology enhance accuracy. Furthermore, this uniquely integrates recent findings protein-protein interaction networks microRNA pathways, exploring novel combinations proteomic, genomic, epigenomic biomarkers that provide new insights into AD’s molecular mechanisms. Additionally, we discuss integration with advanced neuroimaging techniques, emphasizing revolutionize diagnostics. Although large-scale validation still needed, represent a critical advancement toward more accessible, cost-effective, tools AD.

Language: Английский

Citations

5
Blood tests could soon predict your risk of Alzheimer’s DOI Creative Commons

Alison Abbott

Nature, Journal Year: 2024, Volume and Issue: 632(8024), P. 243 - 245

Published: Aug. 7, 2024

Language: Английский

Citations

4
Spatiotemporal Dysregulation of Neuron–Glia Related Genes and Pro-/Anti-Inflammatory miRNAs in the 5xFAD Mouse Model of Alzheimer’s Disease DOI Open Access
M. Di Ianni, Miriam Corraliza-Gómez, Tiago Costa-Coelho

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(17), P. 9475 - 9475

Published: Aug. 31, 2024

Alzheimer's disease (AD), the leading cause of dementia, is a multifactorial influenced by aging, genetics, and environmental factors. miRNAs are crucial regulators gene expression play significant roles in AD onset progression. This exploratory study analyzed levels 28 genes 5 (miR-124-3p, miR-125b-5p, miR-21-5p, miR-146a-5p, miR-155-5p) related to pathology neuroimmune responses using RT-qPCR. Analyses were conducted prefrontal cortex (PFC) hippocampus (HPC)

Language: Английский

Citations

4